Adding pitavastatin to chemotherapy for resistant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a statin (pitavastatin) to chemotherapy can help people whose non-small cell lung cancer has stopped responding to standard treatments. The treatment is personalized based on a lab test of your tumor cells to find the best chemo combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have non-small cell lung cancer that has progressed after at least two prior treatments.
- You have at least one measurable tumor (a lung tumor at least 1 cm, or a lymph node at least 1.5 cm on CT scan).
- You are in reasonably good health, able to care for yourself (ECOG 0-2), and expected to live at least 6 more months.
- Your blood counts (white blood cells, platelets, hemoglobin) and liver, kidney, and clotting function are within acceptable levels.
- Any brain metastases, if present, are controlled and not causing symptoms for at least 2 months.
- You have no active bleeding, recent blood clots, or severe heart conditions, and you are not allergic to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests a new way to choose the best treatment for your lung cancer by creating a model of your tumor in the lab. It may help doctors find the most effective therapy for you.
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
This trial compares pembrolizumab (an immunotherapy drug) given alone versus combined with chemotherapy for women with advanced non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if adding chemotherapy improves outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.